Issue CMS has called this meeting of the panel to consider and make recommendations to CMS regarding the evidence that supports the use of pharmacogenomic testing in the diagnosis and treatment of cancer. Currently, Medicare does not have a National Coverage Determination for using such tests for diagnosis or treatment of cancer. Evidence from clinical studies suggests that tumor genetic factors...
CMS is pleased to announce the posting of 2010 Physician Quality Reporting Initiative (PQRI) educational products to the PQRI webpage at www.cms.hhs.gov/PQRI.
CMS is hosting a Listening Session on the 2011 Physician Quality Reporting Initiative (PQRI). The purpose of this listening session is to discuss and solicit feedback on the individual quality measures and measures groups being considered for possible inclusion in the proposed set of quality measures for use in the 2011 PQRI program and key components of the design of the PQRI program, such as...
The Agency for Healthcare Research and Quality's (AHRQ) Technology Assessment Program will be posting a draft technology assessment for review on December 16, 2009. This draft is entitled "Update of Horizon Scan Reports of Genetic Tests Currently Available for Clinical Use." If you are interested in reviewing this document, please visit: http://www.ahrq.gov/clinic/ta/tareview.htm. The document...
This Special Open Door Forum will focus on a new reporting option, available for the 2010 PQRI and eRx Incentive Program, known as the Group Practice Reporting Option (GPRO). Group practices that are interested in participating in the GPRO for PQRI and/or the eRx Incentive Program must submit a self-nomination letter to CMS by no later than January 31, 2010. Once a group practice (Tax...
In its Semiannual Report to Congress, the Department of HHS Office of Inspector General (OIG) today announced significant audit, investigation, and evaluation accomplishments for FY 2009. OIG reported savings and expected recoveries of $20.97 billion for all of FY 2009. The following areas pertaining to laboratories were identified in the report: End Stage Renal Disease: Separately Billed...